CN101530405B - 柠檬酸及复方柠檬酸在制药中的应用 - Google Patents
柠檬酸及复方柠檬酸在制药中的应用 Download PDFInfo
- Publication number
- CN101530405B CN101530405B CN2009100823347A CN200910082334A CN101530405B CN 101530405 B CN101530405 B CN 101530405B CN 2009100823347 A CN2009100823347 A CN 2009100823347A CN 200910082334 A CN200910082334 A CN 200910082334A CN 101530405 B CN101530405 B CN 101530405B
- Authority
- CN
- China
- Prior art keywords
- citric acid
- chicken
- compound
- group
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 title claims abstract description 276
- 150000001875 compounds Chemical class 0.000 title abstract description 60
- 241000287828 Gallus gallus Species 0.000 claims abstract description 81
- 241000700605 Viruses Species 0.000 claims abstract description 36
- 244000144977 poultry Species 0.000 claims abstract description 17
- 206010064097 avian influenza Diseases 0.000 claims abstract description 11
- 244000144972 livestock Species 0.000 claims abstract description 10
- 208000035143 Bacterial infection Diseases 0.000 claims abstract description 8
- 241000283690 Bos taurus Species 0.000 claims abstract description 6
- 235000015165 citric acid Nutrition 0.000 claims description 89
- 239000003814 drug Substances 0.000 claims description 34
- 241000204031 Mycoplasma Species 0.000 claims description 22
- 241000588724 Escherichia coli Species 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 14
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 claims description 13
- 229960002146 guaifenesin Drugs 0.000 claims description 13
- 208000027312 Bursal disease Diseases 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 10
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- 230000000844 anti-bacterial effect Effects 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 4
- 241000712461 unidentified influenza virus Species 0.000 claims description 3
- 241000702626 Infectious bursal disease virus Species 0.000 claims description 2
- HBGOLJKPSFNJSD-UHFFFAOYSA-N Etamsylate Chemical compound CC[NH2+]CC.OC1=CC=C(O)C(S([O-])(=O)=O)=C1 HBGOLJKPSFNJSD-UHFFFAOYSA-N 0.000 abstract description 12
- 229960004817 etamsylate Drugs 0.000 abstract description 12
- 241001465754 Metazoa Species 0.000 abstract description 9
- 201000010099 disease Diseases 0.000 abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 9
- 238000002474 experimental method Methods 0.000 abstract description 4
- 238000001727 in vivo Methods 0.000 abstract description 3
- 244000052616 bacterial pathogen Species 0.000 abstract description 2
- 230000003612 virological effect Effects 0.000 abstract description 2
- 241000204022 Mycoplasma gallisepticum Species 0.000 abstract 2
- 241000193830 Bacillus <bacterium> Species 0.000 abstract 1
- 208000002979 Influenza in Birds Diseases 0.000 abstract 1
- 210000001072 colon Anatomy 0.000 abstract 1
- 235000013330 chicken meat Nutrition 0.000 description 71
- 238000012360 testing method Methods 0.000 description 46
- 230000006378 damage Effects 0.000 description 23
- 229940079593 drug Drugs 0.000 description 19
- 230000000694 effects Effects 0.000 description 19
- 235000019786 weight gain Nutrition 0.000 description 18
- 230000037396 body weight Effects 0.000 description 17
- 230000004584 weight gain Effects 0.000 description 14
- 208000015181 infectious disease Diseases 0.000 description 13
- 235000013594 poultry meat Nutrition 0.000 description 13
- 208000032843 Hemorrhage Diseases 0.000 description 11
- WBPYTXDJUQJLPQ-VMXQISHHSA-N tylosin Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@H]1C[C@@](C)(O)[C@@H](O)[C@H](C)O1 WBPYTXDJUQJLPQ-VMXQISHHSA-N 0.000 description 11
- 230000036285 pathological change Effects 0.000 description 9
- 231100000915 pathological change Toxicity 0.000 description 9
- 229930194936 Tylosin Natural products 0.000 description 8
- 239000004182 Tylosin Substances 0.000 description 8
- 235000021053 average weight gain Nutrition 0.000 description 8
- 238000007689 inspection Methods 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 229960004059 tylosin Drugs 0.000 description 8
- 235000019375 tylosin Nutrition 0.000 description 8
- 238000005303 weighing Methods 0.000 description 8
- 210000001669 bursa of fabricius Anatomy 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000012856 packing Methods 0.000 description 6
- 231100000614 poison Toxicity 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 239000003440 toxic substance Substances 0.000 description 6
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000000273 veterinary drug Substances 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 208000018569 Respiratory Tract disease Diseases 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 230000023555 blood coagulation Effects 0.000 description 4
- -1 citric acid compound Chemical class 0.000 description 4
- 235000020188 drinking water Nutrition 0.000 description 4
- 239000003651 drinking water Substances 0.000 description 4
- 210000002969 egg yolk Anatomy 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 210000003141 lower extremity Anatomy 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000002976 pectoralis muscle Anatomy 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 206010059866 Drug resistance Diseases 0.000 description 3
- 208000021642 Muscular disease Diseases 0.000 description 3
- 201000009623 Myopathy Diseases 0.000 description 3
- 206010036790 Productive cough Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 238000010306 acid treatment Methods 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 210000000416 exudates and transudate Anatomy 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 210000003097 mucus Anatomy 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 208000031648 Body Weight Changes Diseases 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 208000003322 Coinfection Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 231100000111 LD50 Toxicity 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000954 anitussive effect Effects 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 229940124584 antitussives Drugs 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000004579 body weight change Effects 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 238000003113 dilution method Methods 0.000 description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 2
- 229940126534 drug product Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000001408 fungistatic effect Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 235000004237 Crocus Nutrition 0.000 description 1
- 241000596148 Crocus Species 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 206010018276 Gingival bleeding Diseases 0.000 description 1
- 208000024283 Gingival haemorrhages Diseases 0.000 description 1
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000031814 IgA Vasculitis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000222065 Lycoperdon Species 0.000 description 1
- 241001430197 Mollicutes Species 0.000 description 1
- 206010028470 Mycoplasma infections Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- KJHOZAZQWVKILO-UHFFFAOYSA-N N-(diaminomethylidene)-4-morpholinecarboximidamide Chemical compound NC(N)=NC(=N)N1CCOCC1 KJHOZAZQWVKILO-UHFFFAOYSA-N 0.000 description 1
- 206010071301 Perihepatitis Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 241000768494 Polymorphum Species 0.000 description 1
- 208000027954 Poultry disease Diseases 0.000 description 1
- 208000037111 Retinal Hemorrhage Diseases 0.000 description 1
- 241000209051 Saccharum Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010041235 Snoring Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- WMPXPUYPYQKQCX-UHFFFAOYSA-N Sulfamonomethoxine Chemical compound C1=NC(OC)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 WMPXPUYPYQKQCX-UHFFFAOYSA-N 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 1
- 235000009392 Vitis Nutrition 0.000 description 1
- 241000219095 Vitis Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000003260 anti-sepsis Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 238000009361 aviculture Methods 0.000 description 1
- DMDVEPIJCJGHPE-UHFFFAOYSA-K azane;2-hydroxypropane-1,2,3-tricarboxylate;iron(3+);hydrate Chemical compound N.O.[Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O DMDVEPIJCJGHPE-UHFFFAOYSA-K 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000007905 drug manufacturing Methods 0.000 description 1
- 239000003640 drug residue Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229960004642 ferric ammonium citrate Drugs 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000020676 food antibiotic Nutrition 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 239000004313 iron ammonium citrate Substances 0.000 description 1
- 235000000011 iron ammonium citrate Nutrition 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229960005389 moroxydine Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960000888 rimantadine Drugs 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 238000012306 spectroscopic technique Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229950003874 sulfamonomethoxine Drugs 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009100823347A CN101530405B (zh) | 2009-04-14 | 2009-04-14 | 柠檬酸及复方柠檬酸在制药中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009100823347A CN101530405B (zh) | 2009-04-14 | 2009-04-14 | 柠檬酸及复方柠檬酸在制药中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101530405A CN101530405A (zh) | 2009-09-16 |
CN101530405B true CN101530405B (zh) | 2012-07-18 |
Family
ID=41101399
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009100823347A Active CN101530405B (zh) | 2009-04-14 | 2009-04-14 | 柠檬酸及复方柠檬酸在制药中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101530405B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103690940B (zh) * | 2013-12-26 | 2015-07-01 | 南阳新先锋制药有限公司 | 用于防治禽类肠毒综合症的复方地美硝唑预混剂 |
ES2734584B2 (es) * | 2018-05-22 | 2020-05-04 | Dobecure S L | Etamsilato para el tratamiento de las infecciones por virus del herpes |
CN115721676B (zh) * | 2022-08-05 | 2024-04-26 | 广西大学 | 基于酸梅汤中主要有机酸用于防控鸡大肠杆菌性肠炎 |
-
2009
- 2009-04-14 CN CN2009100823347A patent/CN101530405B/zh active Active
Non-Patent Citations (1)
Title |
---|
Thomson.KR100728722B摘要.德温特数据库.2008,摘要全文. * |
Also Published As
Publication number | Publication date |
---|---|
CN101530405A (zh) | 2009-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103125779B (zh) | 一种肉鸡用生物中药饲料添加剂及其制备方法 | |
CN103719623B (zh) | 预防或缓解断奶仔猪应激综合症的中药饲料添加剂及其制备方法 | |
CN110354139A (zh) | 一种抗猪流行性腹泻病毒感染的组合物及其应用 | |
CN102988363B (zh) | 一种治疗家禽腺胃炎和坏死性肠炎的药物及其制备方法 | |
CN101530405B (zh) | 柠檬酸及复方柠檬酸在制药中的应用 | |
WO2010000207A1 (zh) | 一种天然蒜素片及其制备方法 | |
CN103948656B (zh) | 一种含穿心莲和磷霉素的畜禽用复方药物 | |
CN102920771A (zh) | 一种用于治疗家禽球虫病的药物 | |
WO2016112552A1 (zh) | 牛磺酸在预防和/或治疗由冠状病毒属和/或轮状病毒属病毒引发的疾病中的应用 | |
CN102641261A (zh) | 伏立诺他在制备抗柔嫩艾美耳球虫药物中的应用 | |
CN104971124B (zh) | 一种药物组合物的新用途 | |
CN105380939A (zh) | 染料木黄酮及其药用衍生物在制备抗柔嫩艾美耳球虫药物中的应用 | |
CN105708856B (zh) | 一种用于防治鸡球虫病含凹凸棒石的药物组合物及其制备 | |
CN101780064B (zh) | 对羟基肉桂酸的用途 | |
CN102293764B (zh) | 对羟基肉桂酸的新用途 | |
CN109700832A (zh) | 包含地衣芽孢杆菌和美洲大蠊提取物的药物组合物 | |
CN105748861B (zh) | 抗应激反应的中药组合物,其制备方法和应用 | |
CN101085037A (zh) | 一种兽用中药制剂及其制备方法 | |
CN101972325A (zh) | 用于治疗鸡球虫病的药物组合物及其制备方法 | |
CN112891360A (zh) | 脱氧土大黄苷的新用途 | |
CN113304253A (zh) | 一种辅助预防或辅助治疗新冠肺炎的食物及其应用 | |
CN107349376B (zh) | 一种抗鸡球虫益生药物及其制备方法和应用 | |
CN101757069A (zh) | 治疗鸡混合感染的药物口服液及其制备方法、应用 | |
CN101879171A (zh) | 一种防治鸡白冠病口服液及其制备方法 | |
CN101757209A (zh) | 一种防治对虾白斑病的中西复方药物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160929 Address after: 642150 East Ring Road, Longchang County Industrial Park, Neijiang, Sichuan Patentee after: SICHUAN TONGDA ANIMAL HEALTH TECHNOLOGY CO., LTD. Address before: 100193 Beijing Old Summer Palace West Road, Haidian District, No. 2 Patentee before: He Cheng Patentee before: Zhang Faming Patentee before: Li Shaowen Patentee before: Li Yingchao Patentee before: Li Shumei |